
Argent BioPharma (ASX:RGT) Unlocks Huge Potential as Epilepsy Treatment CannEpil® Gains Traction in Key Markets
Ongoing Revenue Generation and Key Regulatory Milestones Point to Strong Growth for Argent BioPharma in the Biotech Sector Argent Biopharma (ASX:RGT) ADELAIDE, SOUTH AUSTRALIA, AUSTRALIA, February 6, 2025 /EINPresswire.com/ -- Argent BioPharma (ASX: RGT) (OTCQB: RGTLF), a clinical-stage pharmaceutical company, is capturing the attention of investors as its groundbreaking epilepsy treatment, CannEpil®, gains momentum. Valued at $23 million, the company’s risk-adjusted net present value (rNPV) stands at …